Navigation

Archive | Uncategorized

A model for procalcitonin concentrations following birth in non infected preterm neonates

January 25, 2021

Authors Jacqueline A Hannam1,2, Brian J Anderson2, Nick HG Holford1
Affiliations 1Department of Pharmacology & Clinical Pharmacology, University of Auckland; 2 Department of Anaesthesiology, University of Auckland.
Presentation type Oral
Presenters Jacqui Hannam

Attachments


Background: Procalcitonin (PCT) may be used to monitor infection and guide antibiotic therapy (1). However its usefulness in neonates is hampered due to changes following birth and events such as surgery. Methods: PCT concentrations measured in 282 non-infected pre-term and term neonates (22 and 41 weeks gestation) were provided for analysis (2). A turnover model was […]

Continue Reading

Matters close to the heart: adaptation of tacrolimus models to inform therapeutic drug monitoring using the PRIOR approach

January 20, 2021

Authors Ranita Kirubakaran (1,2), David W. Uster (3), Stefanie Hennig (4,5), Jane E. Carland (1,2,6), Richard O. Day (1,2), Sebastian G. Wicha (3), Sophie L. Stocker (1,2,7).
Affiliations 1. St Vincent's Clinical School, The University of New South Wales, Sydney, Australia. 2. Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital Sydney, Australia. 3. Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Germany. 4. Certara, Inc., Princeton, New Jersey, USA. 5. School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia. 6. Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, Australia. 7. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Australia.
Presentation type Oral
Presenters Ranita Kirubakaran

Introduction. External evaluation of published tacrolimus population pharmacokinetic models (n=17) highlighted that no available model accurately describes tacrolimus disposition in heart transplant (HTX) recipients, both with and without concomitant azole antifungal therapy.1 Concomitant azole antifungal therapy alters tacrolimus disposition substantially necessitating dose adjustments. The incorporation of azole antifungal use as a covariate may improve model-predicted […]

Continue Reading

A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults

January 10, 2021

Authors James D Morse (1), L Ignacio Cortinez (2), Brian J Anderson (3)
Affiliations 1 Department of Pharmacology & Clinical Pharmacology, University of Auckland, Park Road, Auckland 023, New Zealand. 2 Department of Anesthesiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago de Chile 8331150, Chile. 3 Department of Anaesthesiology, University of Auckland, Park Road, Auckland 1023, New Zealand.
Presentation type Poster
Presenters James Morse

Attachments

A universal pharmacokinetic model was developed from pooled paediatric and adult data (40.6 postmenstrual weeks, 70.8 years, 3.1-152 kg). A three-compartment pharmacokinetic model with first-order elimination was superior to a two-compartment model to describe these pooled dexmedetomidine data. Population parameter estimates (population parameter variability %) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) […]

Continue Reading

Modeling of The Relationship Between Ustekinumab Exposure, Fecal Calprotectin and Endoscopic Outcomes in Patients with Crohn’s Disease

January 10, 2021

Authors Zhigang Wang (1), Bram Verstockt (2,3), João Sabino (2,3), Séverine Vermeire (2,3), Marc Ferrante (2,3), Paul Declerck (1), Erwin Dreesen (1,4)
Affiliations 1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 2. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 3. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium 4. Department of Pharmacy, Uppsala University, Uppsala, Sweden
Presentation type Oral
Presenters Zhigang Wang

Attachments




Background: Ustekinumab is approved for the treatment of patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis. In the UNITI endoscopy sub-study, only 17.4% of patients on ustekinumab achieved endoscopic response and 10.9% of patients achieved endoscopic remission at week 44 (w44).1 Aims: We aimed to investigate if improved endoscopic outcomes could be achieved through dose optimization […]

Continue Reading

External Evaluation of Vancomycin Models

January 10, 2021

Authors Guangda Ma (1), Eamon Duffy (1, 2), Jacqui Hannam (1), Nick Holford (1)
Affiliations (1) The University of Auckland, (2) Auckland District Health Board
Presentation type Poster
Presenters Guangda Ma

Attachments

Introduction Current clinical evidence supports area under the concentration-time curve (AUC) rather than trough concentrations as a more rational target for vancomycin therapy (1). In mid-2019 practice at Auckland District Health Board Hospitals transitioned from trough concentration to AUC guided dosing supported by Bayesian forecasting using the GAVamycin model implemented in NextDose (www.nextdose.org). To support […]

Continue Reading